TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06768762

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized Feedback
Description: Participants will receive individualized feedback from a coach via email. The feedback will specifically focus on participant responses to the 'Apply Your Knowledge' activities and will correspond with the video lessons. Feedback will be weekly during months 1-3 and monthly during months 4-6.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online exercise program
Description: MOST Energized! Online Exercise Program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online exercise program
Description: MOST Energized! Online Exercise Program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online exercise program
Description: MOST Energized! Online Exercise Program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online exercise program
Description: MOST Energized! Online Exercise Program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online exercise program
Description: MOST Energized! Online Exercise Program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online exercise program
Description: MOST Energized! Online Exercise Program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online exercise program
Description: MOST Energized! Online Exercise Program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online exercise program
Description: MOST Energized! Online Exercise Program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online exercise program
Description: MOST Energized! Online Exercise Program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online exercise program
Description: MOST Energized! Online Exercise Program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online exercise program
Description: MOST Energized! Online Exercise Program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online exercise program
Description: MOST Energized! Online Exercise Program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online exercise program
Description: MOST Energized! Online Exercise Program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online exercise program
Description: MOST Energized! Online Exercise Program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online exercise program
Description: MOST Energized! Online Exercise Program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online exercise program
Description: MOST Energized! Online Exercise Program
Study: NCT06761001

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-PRF
Description: After local anesthesia is injected, alveolar curettage is performed and the socket is irrigated with saline solution. I-PRF is given to patients in the experimental group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: After local anesthesia is injected, alveolar curettage is performed and the socket is irrigated with saline solution.
Study: NCT06776198

Intervention type: DRUG
Intervention: Chemotherapy
Description: Group IE/F: After progression, try LRRC15 ADC + PD-1 inhibitors; Group IE: After progression, try simple anti-PD-1 inhibitors; Group F: After progression, try LRRC15 ADC; Group D: After progression, try B7-H3 ADC or other irrinotecan analogue

Intervention type: DRUG
Intervention: Chemotherapy
Description: Group IE/F: After progression, try LRRC15 ADC + PD-1 inhibitors; Group IE: After progression, try simple anti-PD-1 inhibitors; Group F: After progression, try LRRC15 ADC; Group D: After progression, try B7-H3 ADC or other irrinotecan analogue

Intervention type: DRUG
Intervention: Chemotherapy
Description: Group IE/F: After progression, try LRRC15 ADC + PD-1 inhibitors; Group IE: After progression, try simple anti-PD-1 inhibitors; Group F: After progression, try LRRC15 ADC; Group D: After progression, try B7-H3 ADC or other irrinotecan analogue

Intervention type: DRUG
Intervention: Chemotherapy
Description: Group IE/F: After progression, try LRRC15 ADC + PD-1 inhibitors; Group IE: After progression, try simple anti-PD-1 inhibitors; Group F: After progression, try LRRC15 ADC; Group D: After progression, try B7-H3 ADC or other irrinotecan analogue
Study: NCT06763653

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ULF therapy
Description: ultra low frequency spinal cord stimulation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CMM
Description: conventional medical management

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CMM
Description: conventional medical management
Study: NCT06769633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Givinostat Hydrochloride
Description: Cohort 1 - from 4 to 6 years old

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Givinostat Hydrochloride - Cohort 2
Description: Cohort 2 - from 2 to 4 years old
Study: NCT06770257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin, cytarabine liposomes
Description: First induction: 100 units/m\^2 by 90-minute IV infusion on Days 1, 3, 5. Second induction: 100 units/m\^2 by 90-minute IV infusion on Days 1 and 3. Consolidation therapy: 65 units/m\^2 by 90-minute IV infusion on Days 1 and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin, cytarabine liposomes
Description: First induction: 100 units/m\^2 by 90-minute IV infusion on Days 1, 3, 5. Second induction: 100 units/m\^2 by 90-minute IV infusion on Days 1 and 3. Consolidation therapy: 65 units/m\^2 by 90-minute IV infusion on Days 1 and 3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: Given SC on days 1-7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO on days 1-14 or 1-21 or 1-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO on days 1-14 or 1-21 or 1-28

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venetoclax
Description: Given PO on days 1-14 or 1-21 or 1-28
Study: NCT06775977

Intervention type: DIAGNOSTIC_TEST
Intervention: Contrast Enhanced Ultrasound (CEUS)
Description: Contrast Enhanced Ultrasound (CEUS) refers to the observation under ultrasound after the injection of ultrasound contrast agents, such as SonoVue or Lumason.
Study: NCT06769815

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: For febrile children at the time of inclusion : 6.25 ml to 8.25 ml of blood ; For non febrile children at the time of inclusion : 4 ml of blood ; For pregnant women at the time of inclusion : 5 ml of peripheral blood, 5 ml of placental blood, 20 to 40 ml of umbilical cord blood ; For new borns : drop of blood on child's heel each month and 5 ml of blood the 12th and last month.

Intervention type: OTHER
Group type: OTHER
Intervention: Urine sample
Description: For febrile children : 10 ml of urine

Intervention type: OTHER
Group type: OTHER
Intervention: oropharyngeal sample
Description: For febrile children : oropharyngeal swab sampling

Intervention type: OTHER
Group type: OTHER
Intervention: Optionnal : stool sample
Description: For febrile children (only as part of the care of the child) : 5g stool

Intervention type: OTHER
Group type: OTHER
Intervention: Optionnal : cerebrospinal fluid
Description: For febrile children (only as part of the care of the child in case of suspected meningitis) : 4 additional drops of cerebrospinal fluid
Study: NCT05654337

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expert health counseling
Description: Expert advice on dietary education, lifestyle change, and physical exercise schedule
Study: NCT06769815

Intervention type: OTHER
Group type: OTHER
Intervention: placental biopsy
Description: For pregnant women : placental biopsy the size of 2 rice grains
Study: NCT06780618

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RICE
Description: 150 g of brown rice from Aek Sibundong variant at once

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: rice wheat (placebo)
Description: 150 g of white rice from Setra Ramos variant at once
Study: NCT06774313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-142
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-142
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-142
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-142
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-142
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-142
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-142
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-142
Description: Subcutaneous (SC) Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-142
Description: Subcutaneous (SC) Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SC Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SC Injection
Study: NCT05757167

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Malaria High-Sensitivity Rapid Diagnostic Test (HS-RDT)
Description: Detection of Plasmodium falciparum HRP-II antigen1~Method: Lateral Flow; Time to Result: 20 minutes; Sample Type: Fingerstick Whole Blood; Sample Volume: 5µl; Storage Conditions: 1-30°C; Shelf Life: 12 months; Sensitivity/Specificity: 99.0%/98.6%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine 20 Mg-120 Mg Oral Tablet
Description: oral tablets: 6 doses of 80/480 mg over 3 days
Study: NCT05633836

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluorescence guided surgery
Description: During exploratory laparoscopy or at the end of macroscopically complete cytoreduction surgery, indocyanine green fluorescence-guided surgery is performed to identify peritoneal carcinoma lesions not visible in white light
Study: NCT06455423

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chin tuck in exercises
Description: Chin tuck in exercises
Study: NCT06217198

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deprexis
Description: Deprexis is an internet-delivered treatment for depressive symptoms and related functional impairment. The intervention draws from various theoretical frameworks and consists of 12 modules: 10 core content modules and an introductory and summary module. Deprexis is designed to be interactive, includes answering questions and learning techniques and concepts through instruction and examples.
Study: NCT05581004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7502175
Description: RO7502175 will be administered as per the schedules specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7502175
Description: RO7502175 will be administered as per the schedules specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7502175
Description: RO7502175 will be administered as per the schedules specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7502175
Description: RO7502175 will be administered as per the schedules specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as per the schedules specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as per the schedules specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as per the schedules specified in the respective arms.
Study: NCT05350072

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAY736
Description: ianalumab s.c.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo s.c.
Study: NCT06126276

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study: NCT05416398

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise, High Intensity Interval Training
Description: Aerobic exercise is a form of exercise done by consuming oxygen in order to give energy to the body. High Intensity Interval Training consists of low-intensity periods of active rest combined with short periods of intense exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise, High Intensity Interval Training
Description: Aerobic exercise is a form of exercise done by consuming oxygen in order to give energy to the body. High Intensity Interval Training consists of low-intensity periods of active rest combined with short periods of intense exercise.
Study: NCT06455423

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic Extension Exercise
Description: Thoracic Extension Exercise

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Extension Exercise
Description: Thoracic Extension Exercise
Study: NCT06126276

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study: NCT06455423

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scapular Retraction Exercises
Description: Scapular Retraction Exercises
Study: NCT06045897

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological sampling
Description: Blood samples will be taken for genetic, epigenetic, proteomic, and metabolomic studies.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological sampling
Description: Blood samples will be taken for genetic, epigenetic, proteomic, and metabolomic studies.
Study: NCT06455423

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scapular Retraction Exercises
Description: Scapular Retraction Exercises

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hot Pack
Description: Hot Pack

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hot Pack
Description: Hot Pack

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: Trans Cutaneous Electric Nerve Stimulation (TENS)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: Trans Cutaneous Electric Nerve Stimulation (TENS)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ELDOA
Description: ELDOA exercises
Study: NCT05148260

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Learning Through Play plus (LTP+)
Description: Group-1: Experimental (n=40 participants) will receive the LTP+ which consist of a total of 12-group integrated treatment sessions lasting approximately 60-90 minutes per session every fortnight with 10 mother/child pair per sub-group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Group-2: Controlled (n=40 participants) will receive 'psychoeducation' which consist of a total of 12-group sessions lasting approximately 60-90 minutes per session every fortnight with 10 mother-child pair per sub-group.
Study: NCT06126276

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neratinib Maleate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib Maleate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO
Study: NCT05300958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferoxamine Plus Chemotherapy
Description: Deferoxamine：50mg/kg+500ml normal saline (NS)
Study: NCT06206772

Intervention type: DIAGNOSTIC_TEST
Intervention: Resting state HD-EEG recording
Description: All subjects will be recorded with a resting state HD-EEG recording. 12 minutes in the eyes closed and 12 minutes in the eyes open condition.

Intervention type: DIAGNOSTIC_TEST
Intervention: Resting state HD-EEG recording
Description: All subjects will be recorded with a resting state HD-EEG recording. 12 minutes in the eyes closed and 12 minutes in the eyes open condition.

Intervention type: DIAGNOSTIC_TEST
Intervention: Resting state HD-EEG recording
Description: All subjects will be recorded with a resting state HD-EEG recording. 12 minutes in the eyes closed and 12 minutes in the eyes open condition.

Intervention type: DIAGNOSTIC_TEST
Intervention: Resting state HD-EEG recording
Description: All subjects will be recorded with a resting state HD-EEG recording. 12 minutes in the eyes closed and 12 minutes in the eyes open condition.
Study: NCT06283134

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BioTTT001 hepatic artery infusion
Description: BioTTT001 monotherapy period: BioTTT001 5×10\^7 VP/5×10\^8 VP/5×10\^9 VP/1×10\^10 VP hepatic artery infusion, administered every 2 weeks, for a total of two doses after enrollment.~BioTTT001 in combination with toripalimab and regorafenib period: BioTTT001 5×10\^7 VP/5×10\^8 VP/5×10\^9 VP/1×10\^10 VP hepatic artery infusion, D2 and D16, 4 weeks per cycle， and the dose of BioTTT001 will be determined according to the safety observation results in the monotherapy phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: toripalimab
Description: BioTTT001 in combination with toripalimab and regorafenib period: toripalimab 80mg intravenous D1 and D15, 4 weeks per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regorafenib
Description: BioTTT001 in combination with toripalimab and regorafenib period: regorafenib 80 mg oral administration, D1-D21, 4 weeks per cycle.
Study: NCT04942522

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: probiotics PS128
Description: 6×10\^10 CFU/capsule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: probiotics PS128
Description: 6×10\^10 CFU/capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo (Microcrystalline cellulose )
Description: 450 mg/capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo (Microcrystalline cellulose )
Description: 450 mg/capsule
Study: NCT06045897

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological sampling
Description: Blood samples will be taken for genetic, epigenetic, proteomic, and metabolomic studies.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological sampling
Description: Blood samples will be taken for genetic, epigenetic, proteomic, and metabolomic studies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Participants will undergo a virtual reality task using a head-mounted display, and their multidimensional self will be assessed prior to and after the task via the self-reference effect on episodic memory.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Participants will undergo a virtual reality task using a head-mounted display, and their multidimensional self will be assessed prior to and after the task via the self-reference effect on episodic memory.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Participants will undergo a virtual reality task using a head-mounted display, and their multidimensional self will be assessed prior to and after the task via the self-reference effect on episodic memory.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Voice recording
Description: A double channel audio recorder will be used during 30 min to assess voice characteristics of all subjects.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Voice recording
Description: A double channel audio recorder will be used during 30 min to assess voice characteristics of all subjects.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Voice recording
Description: A double channel audio recorder will be used during 30 min to assess voice characteristics of all subjects.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Voice recording
Description: A double channel audio recorder will be used during 30 min to assess voice characteristics of all subjects.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Voice recording
Description: A double channel audio recorder will be used during 30 min to assess voice characteristics of all subjects.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Voice recording
Description: A double channel audio recorder will be used during 30 min to assess voice characteristics of all subjects.